



Radek C Skoda

Kontakt

Radek C Skoda

Publikationen (9)

Stetka J, Usart M, Kubovcakova L, Rai S, Rao T, Sutter J, Hao-Shen H, Dirnhofer S, Geier F, Bader M, Passweg J, Manolova V, Dürrenberger F, Ahmed N, Schroeder T, Ganz T, Nemeth E, Silvestri L, Nai A, Camaschella C, Skoda R. Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms. *Blood* 2023; 141:2127-2140.

Meyer S, Steinmann E, Lehmann T, Muesser P, Passweg J, Skoda R, Tsakiris D. Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera. *Biomed Res Int* 2017; 2017:9876819.

Holbro A, Skoda R, Lundberg P, Passweg J, Buser A, Lehmann T. Erythropoietin receptor mutation--a rush of blood to the head?. *Ann Hematol* 2015; 94:1229-31.

Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, Girsberger S, Lehmann T, Passweg J, Stern M, Beisel C, Kralovics R, Skoda R. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. *Blood* 2014; 123:2220-8.

Girsberger S, Karow A, Lundberg P, Dirnhofer S, Lehmann T, Passweg J, Tichelli A, Skoda R, Rovó A. JAK2 V617F-mutated myeloproliferative neoplasia developing five years after wild-type JAK2 acute myeloid leukemia: a case report. *Acta Haematol* 2012; 129:23-5.

Schaub F, Lehmann T, Looser R, Hao-Shen H, Tichelli A, Skoda R. Transition to homozygosity does not appear to provide a clonal advantage to hematopoietic progenitors carrying mutations in TET2. *Blood* 2011; 117:2075-6.

Passamonti F, Elena C, Schnittger S, Skoda R, Green A, Girodon F, Kiladjian J, McMullin M, Ruggeri M, Besses C, Vannucchi A, Lippert E, Gisslinger H, Rumi E, Lehmann T, Ortman C, Pietra D, Pascutto C, Haferlach T, Cazzola M. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. *Blood* 2011; 117:2813-6.

Schaub F, Looser R, Li S, Hao-Shen H, Lehmann T, Tichelli A, Skoda R. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. *Blood* 2010; 115:2003-7.

Kralovics R, Cazzola M, Pietra D, Passamonti F, Tichelli A, Tiedt R, Brutsche M, Buser A, Teo S, Skoda R. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. *Blood* 2005; 106:3374-6.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch